Table 4.
Patients’ baseline characteristics according to history of percutaneous coronary intervention (PCI)
| Patients, n | non-PCI | PCI | p value |
|---|---|---|---|
| 184 | 50 | ||
| Age (years), mean ± SD | 58.9 ± 11.1 | 63.4 ± 9.1 | 0.01 |
| Male sex, n (%) | 149 (81) | 42 (74) | 0.35 |
| BMI (kg/m2), mean ± SD | 27.7 ± 3.8 | 27.4 ± 4.4 | 0.56 |
| Exam interval (months), median (IQR) | 33.4 (22.0 - 53.1) | 26.9 (15.0 - 37.2) | < 0.01 |
| Baseline SSS, median (IQR) | 4 (1 - 8) | 16 (10 - 21) | < 0.001 |
| Clinical risk factors | |||
| Hypertension, n (%) | 91 (49) | 26 (52) | 0.87 |
| Diabetes, n (%) | 20 (11) | 10 (20) | 0.10 |
| Dyslipidemia, n (%) | 89 (48) | 36 (72) | < 0.01 |
| Family history of CAD, n (%) | 79 (43) | 20 (40) | 0.75 |
| Glucose intolerance, n (%) | 6 (3) | 4 (8) | 0.23 |
| Current smoker, n (%) | 22 (12) | 3 (6) | 0.31 |
| Past smoker, n (%) | 39 (21) | 16 (32) | 0.13 |
| Positive stress test, n (%) | 18 (10) | 8 (16) | 0.21 |
| History of MI, n (%) | 2 (1) | 16 (32) | < 0.001 |
| CAD progression, n (%) | 82 (45) | 35 (70) | < 0.001 |
| Medication use | |||
| Beta-blockers, n (%) | 21 (11) | 14 (28) | 0.01 |
| ACEI/ARB, n (%) | 31 (17) | 14 (28) | 0.10 |
| Antiplatelet, n (%) | 18 (10) | 28 (56) | <0.001 |
| Statin, n (%) | 38 (21) | 21 (42) | <0.01 |
SD: standard deviation; BMI: body mass index; SSS: segment stenosis score; IQR: interquartile range; CAD: coronary artery disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.